Audentes Therapeutics Inc (NASDAQ:BOLD) on Focus After Report of More Shorts

May 18, 2018 - By Adrian Mccoy

The stock of Audentes Therapeutics Inc (NASDAQ:BOLD) registered an increase of 5.68% in short interest. BOLD’s total short interest was 2.28 million shares in May as published by FINRA. Its up 5.68% from 2.15M shares, reported previously. With 280,200 shares average volume, it will take short sellers 8 days to cover their BOLD’s short positions. The short interest to Audentes Therapeutics Inc’s float is 13.26%.

The stock increased 21.91% or $7.44 during the last trading session, reaching $41.39. About 1.87 million shares traded or 372.69% up from the average. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has risen 72.67% since May 18, 2017 and is uptrending. It has outperformed by 61.12% the S&P500.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.52 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

More notable recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were published by: Seekingalpha.com which released: “Audentes Therapeutics’ Upcoming Catalysts” on May 03, 2018, also Seekingalpha.com with their article: “Genomic Medicine: Catch The Gene Therapy Wave” published on May 14, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018. More interesting news about Audentes Therapeutics, Inc. (NASDAQ:BOLD) were released by: Seekingalpha.com and their article: “Audentes Therapeutics: Key Program Updates” published on May 12, 2018 as well as Streetinsider.com‘s news article titled: “Audentes Therapeutics (BOLD) Plunges 7.5% After Reporting Data from Phase 1/2 Clinical Trial of AT132 in patients …” with publication date: May 16, 2018.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.